SCAP and lung carcinoma: Our results may serve as a reference for the design of future clinical trials of therapeutic modalities that target the SREBP-1/hsa-miR-497-5p/SCAP/FASN oncometabolic signaling axis to overcome chemoresistance in patients with lung cancer.